medigraphic.com

2017, Number 2

<< Back Next >>

Rev Hematol Mex 2017; 18 (2)

Identification of molecular disorders in pediatric patients with diagnosis of acute leukemia

Zapata-Tarres M, Sánchez-Huerta JL, Angeles-Floriano T, Parra-Ortega I, Klunder-Klunder M, Vilchis-Ordoñez A, Dorantes-Acosta E, Juárez-Villegas L, Sánchez-Urbina R, López-Martínez B

Language: Spanish
References: 29
Page: 47-57
PDF size: 275.51 Kb.


ABSTRACT

Background: Acute leukemias are the most common cancer in childhood. Immunological and cytogenetics classification are main prognostic factors and determine treatment. In Mexico, cytogenetic classification has been limited.
Objetive: To evaluate a panel of 28 genetic disorders in pediatric patients with diagnosis of acute leukemia.
Material and Method: A descriptive, transversal, prospective study, done from January 2013 to November 2014, in which we analyzed 28 translocations with 80 breakpoints of the commercial HemaVisionχ2 RT-PCR kit (DNA-Technology Denmark) in samples from patients with acute leukemia.
Results: 84 patients were included, 67 with acute lymphoblastic leukemia and 17 with acute myeloid leukemia, the age group with more cases was from 2 to 3 years. We identified 25 (40%) patients with the acute lymphoblastic leukemia and 6 patients with acute myeloid leukemia with some molecular cytogenetic alteration. The cytogenetic alterations identified were translocations: t(12;21) (8p13q22) and t(9;22) (q34q11).
Conclusion: The results of the identification of the molecular alterations allowed the physician to have one more resource to stratify the risk of those patients who were classified with habitual risk.


REFERENCES

  1. Mullighan CH, et al. Acute lymphoblastic leukemia. Lancet 2013;381(9881).

  2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030-43.

  3. Pérez Saldivar ML, et al. Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer 2011;11:355.

  4. Khalid S, et al. Retrospective, review of pediatric patients with acute lymphoblastic leukemia: a single center experience. Indian J Pathol Microbiol 2010 Oct- Dec;53(4):704-10.

  5. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005;23:6285-6295.

  6. Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. Concepts of human leukemic development. Oncogene 2004;20;23(43):7164-77.

  7. Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin N Am 2009;23:655-674.

  8. Chow EJ, Kamineni A, Daling JR, Fraser A, et al. Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis. Arch of Pediatr Adolesc Med 2009;163(10):887-894.

  9. Pui CH, Carroll WL, Meshinchi S, Arceci R. Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 2011;29:551-565.

  10. Abdullaev Fl, Rivera-Luna R, Roitenburd-Belacortu V, Espinosa-Aguirre J. Pattern of childhood cancer mortality in Mexico. Arch Med Res 2000;31:526-531.

  11. Pullen J, Shuster JJ, Link M, Borowitz M, Amylon M, Carroll AJ et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 1999;13 (11):1696-1707.

  12. Woo J, et al. Childhood B-acute lymphoblastic leukemia: a genetic update. Experimental Hematology & Oncology 2014;3:16.

  13. Möricke A, Zimmermann M, Reiter A, Gadner H, et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr 2005;217(6):310-320.

  14. Van der Burg M, Smit B, Brinkhof B, et al. A single split-signal FISH probe set allows detection of TAL1 translocations as well as SIL-TAL1 fusion genes in a single test. Leukemia 2002;16:755-761.

  15. Kim HJ, Oh HJ, Lee JW, Jang PS, et al. Utility of a multiplex reverse transcriptase polymerase chain reaction assay (HemaVision) in the evaluation of genetic abnormalities in Korean children with acute leukemia: a single institution study. Korean J Pediatr 2013;56(6):247-253.

  16. Vásquez G, Ramírez JL, Posada A, Sierra M y col. Leucemia linfoide aguda: estudio citogenético en niños atendidos en el Hospital Universitario San Vicente de Paúl Medellín en el periodo 1998-2001. Iatreia 2002;15(4):217-225.

  17. Solís MV, De los Ángeles M, Ruiz E, Carrillo JM y col. Citogenética y citoquímica de pacientes con leucemia en dos hospitales neotropicales. Int J Tropical Biol Conservation 2000;48(2-3):707-718.

  18. Venegas P, Rivera J. Estudios citogenéticos en niños con leucemia linfocítica aguda-B en Costa Rica. Revista de Biología Tropical 2004;52(3): 551.

  19. Sierra-Martínez M, Aguilar F, Cruz R. J, García M, Vergara D. Frecuencia de los hallazgos citogenéticos en pacientes con enfermedades hematológicas que acuden al Hospital Juárez de México. Rev Sal Pub y Nut 2000;2.

  20. Gómez-Almaguer D, Marcos-Ramírez ER, Montaño-Figueroa EH, Ruiz-Argüelles GJ, Best-Aguilera CR, et al. Acute leukemia characteristics are different around the world: the Mexican perspective. Clin Lymphoma Myeloma Leuk 2017;17(1):46-51.

  21. Ruiz-Argüelles GJ. Promyelocytic leukemia in Mexican mestizos. Blood 1997;89:348.

  22. Ruiz-Delgado GJ, Macías-Gallardo J, Lutz-Presno J, Garcés- Eisele J, Hernández-Arizpe A, Montes-Montiel M, Ruiz- Argüelles GJ. Core binding factor acute myeloid leukemia (CBF-AML) in México: a single institution experience. Rev Invest Clin 2011;63:25-30.

  23. Cuervo-Sierra J, Jaime-Pérez JC, Martínez-Hernández RA, García-Sepúlveda RD, et al. Prevalence and clinical significance of FLT3 mutation status in acute myeloid leukemia patients: A Multicenter Study. Arch Med Res 2016 Apr;47:172-179.

  24. Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood 2013;121:1935-1943.

  25. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Gómez- Rangel JD, Ruiz-Delgado GJ. More on geographic hematology: the breakpoint cluster regions of the PML/RARalpha fusion gene in Mexican Mestizo patients with promyelocytic leukemia are different from those in Caucasians. Leuk Lymphoma 2004;45:1365-1368.

  26. Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline- based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol 2014;93(12):2001-2010.

  27. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in highrisk acute lymphoblastic leukemia. Cancer Cell 2012; 22:153-66.

  28. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010;42:338-42.

  29. Zhang J, Mullighan CG, Harvey RC, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 2011;118:3080-7.




2020     |     www.medigraphic.com